Published in J Pharmacol Exp Ther on December 01, 1988
In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest (1994) 1.53
Effect of nitric oxide on circular muscle of the canine small intestine. J Physiol (1991) 1.34
Characteristic features of inhibitory junction potentials evoked by single stimuli in the guinea-pig isolated taenia caeci. J Physiol (1995) 1.09
Nitric oxide-mediated inhibitory response of rat proximal colon: independence from changes in membrane potential. Br J Pharmacol (1994) 0.98
Inhibition of sphincter of Oddi function by the nitric oxide carrier S-nitroso-N-acetylcysteine in rabbits and humans. J Clin Invest (1994) 0.94
Partial mediation by nitric oxide of the relaxation of human isolated detrusor strips in response to electrical field stimulation. Br J Clin Pharmacol (1993) 0.93
Nitric oxide-mediated relaxation without concomitant changes in cyclic GMP content of rat proximal colon. Br J Pharmacol (1996) 0.81
N-hydroxylamine is not an intermediate in the conversion of L-arginine to an activator of soluble guanylate cyclase in neuroblastoma N1E-115 cells. Biochem J (1991) 0.75
Impairment of relaxations to acetylcholine and nitric oxide by a phorbol ester in rat isolated aorta. Br J Pharmacol (1990) 0.75
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (1999) 3.20
Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 3.03
Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol (1992) 2.07
Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia (2007) 2.06
The diposi tion of morphine in surgical patients. Clin Pharmacol Ther (1975) 1.83
The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet (1976) 1.82
Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery. Biotechnology (N Y) (1995) 1.78
Decreased vascular relaxation in hypertension. J Pharmacol Exp Ther (1976) 1.72
Differential selectivity of endothelium-derived relaxing factor and nitric oxide in smooth muscle. Br J Pharmacol (1987) 1.70
Investigation of the Karnofsky Performance Status as a measure of quality of life. Health Psychol (1984) 1.69
Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol (1983) 1.68
Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation (2005) 1.66
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol (2000) 1.64
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem (2000) 1.60
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther (2001) 1.54
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation (2001) 1.46
Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol (2000) 1.45
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev (2001) 1.43
Correlation between the anaesthetic effect of halothane and saturable binding in brain. Nature (1989) 1.42
Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys (1982) 1.38
Nitrous oxide analgesia: reversal by naloxone and development of tolerance. J Pharmacol Exp Ther (1977) 1.35
Nitrous oxide "analgesia": resemblance to opiate action. Science (1976) 1.34
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med (2000) 1.28
Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology (1976) 1.26
Release of norepinephrine in the central nervous system by theophylline and caffeine. Eur J Pharmacol (1970) 1.26
NMR spectral analysis of kinetic data using natural lineshapes. Magn Reson Med (1990) 1.25
Relationship of pentazocine plasma levels to pharmacological activity in man. Clin Pharmacol Ther (1969) 1.24
The release of endothelium-derived relaxant factor is calcium dependent. Blood Vessels (1985) 1.23
Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem (1996) 1.21
Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol (2001) 1.18
Minor head injury: attempts at clarifying the confusion. Brain Inj (1996) 1.14
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation (2001) 1.13
Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension (1995) 1.11
Characterization of adenosine receptors in the rat isolated aorta. Gen Pharmacol (1994) 1.10
Differences between the effects of dopamine and apomorphine on rat aortic strips. Eur J Pharmacol (1975) 1.09
Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther (1975) 1.08
Norepinephrine in blood vessels: concentration, binding, uptake and depletion. J Pharmacol Exp Ther (1971) 1.08
Resistance of noradrenaline in blood vessels to depletion by 6-hydroxydopamine or immunosympathectomy. Br J Pharmacol (1972) 1.07
Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci (2001) 1.06
Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526. J Pharmacol Exp Ther (1984) 1.05
Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res (1996) 1.03
Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res (1994) 1.02
Endothelin levels increase in rat focal and global ischemia. J Cereb Blood Flow Metab (1994) 1.02
Assessment of level of consciousness following severe neurological insult. A comparison of the psychometric qualities of the Glasgow Coma Scale and the Comprehensive Level of Consciousness Scale. J Neurosurg (1984) 1.02
Age-related changes in vascular responsiveness to cyclic nucleotides and contractile agonists. J Pharmacol Exp Ther (1974) 1.02
MR studies of retinal oxygenation. Vision Res (2001) 1.01
Characterization and function of bradykinin receptors in vascular endothelial cells. J Pharmacol Exp Ther (1988) 1.01
Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. Eur J Pharmacol (1992) 1.01
Tolerance to nitrous oxide analgesia in rats and mice. Anesthesiology (1979) 1.01
Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol (2000) 1.01
Validation of structural and functional lesions of diabetic retinopathy in mice. Mol Vis (2010) 1.00
Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells. Hum Gene Ther (1991) 1.00
Catecholamine mechanisms in the stimulation of mouse locomotor activity by nitrous oxide and morphine. Eur J Pharmacol (1983) 0.99
Analgesic action and pharmacokinetics of morphine and diazepam in man: an evaluation by sensory decision theory. Anesthesiology (1979) 0.97
beta-Adrenergic receptor decrease in diabetic rat hearts. Life Sci (1980) 0.97
Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther (1992) 0.97
Analysis of responses to endothelins in the rabbit pulmonary and systemic vascular beds. J Appl Physiol (1985) (1991) 0.97
Size-dependent control of the binding of biotinylated proteins to streptavidin using a polymer shield. Nature (2001) 0.96
Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol (1993) 0.96
The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist. Eur J Pharmacol (1985) 0.96
In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol (1995) 0.95
Temperature control of biotin binding and release with A streptavidin-poly(N-isopropylacrylamide) site-specific conjugate. Bioconjug Chem (1999) 0.95
Measurement of blood-retinal barrier breakdown in endotoxin-induced endophthalmitis. Invest Ophthalmol Vis Sci (1995) 0.94
Antagonism of general anesthesia by naloxone in the rat. Anesthesiology (1977) 0.94
Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther (1987) 0.94
What is the relationship between the endothelium derived relaxant factor and nitric oxide? Life Sci (1989) 0.94
Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor. Hypertension (1985) 0.93
Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res (1993) 0.93
Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol (1999) 0.93
Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol (1995) 0.93
Blood-retinal barrier breakdown caused by diode vs argon laser endophotocoagulation. Arch Ophthalmol (1992) 0.92
Transcorneal oxygenation of the preretinal vitreous. Arch Ophthalmol (1994) 0.92
Effects of the leukotrienes on the vasculature and blood pressure of different species. J Pharmacol Exp Ther (1984) 0.92
Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther (1994) 0.92
SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors. Eur J Pharmacol (1985) 0.91
A simple and inexpensive cannula technique for chemical stimulation of the brain. Physiol Behav (1970) 0.91
In vivo imaging of breakdown of the inner and outer blood-retinal barriers. Invest Ophthalmol Vis Sci (1992) 0.91
A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol (2000) 0.91
Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol (2001) 0.91
Founder's Award, Society for Biomaterials. Sixth World Biomaterials Congress 2000, Kamuela, HI,May 15-20, 2000. Really smart bioconjugates of smart polymers and receptor proteins. J Biomed Mater Res (2000) 0.90
Renal microvascular effects of endothelin. Am J Physiol (1990) 0.90
Analgesic activity and central nervous system distribution of the optical isomers of pentazocine in the rat. J Pharmacol Exp Ther (1971) 0.90
A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res (1994) 0.90
Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum Gene Ther (1992) 0.90
Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther (1986) 0.89
Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol (1996) 0.89
The effect of caffeine and theophylline on the disposition of brain serotonin in the rat. Eur J Pharmacol (1972) 0.89
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem (1986) 0.89
Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res (1997) 0.88